Aeon Global Health, the operating arm of Authentidate Holding Corp., a growth-oriented provider of personalized, clinically actionable medical informatics and telemedicine, announced today that it has agreed with Sabal Therapeutics, LLC to be the primary laboratory marketer of Naprosyn, the branded naproxen oral suspension USP. Under the agreement, Aeon will become the exclusive clinical laboratory marketing representative of Sabal and will market the drug alongside of its industry-leading drug monitoring service, thus providing physicians with an integrated, non-opiate solution for pain management.

In a recent study of 5,500 patients, it was concluded that both NSAIDs and opioids provided the same level of acute pain relief. "With the declaration in October 2017 by President Trump that the opioid epidemic is a nationwide public health emergency, we believe that the combination of providing an alternative to these drugs with our state-of-the-art drug monitoring services will be a welcome alternative for pain management," said Sonny Roshan, Chairman and Chief Executive Officer of Aeon Global Health. "Moreover, we believe that combining our testing with this unique pain medication alternative can result in both improved patient outcomes and a reduction in adverse drug reactions so common with some of the opioids. Aeon is committed to offering unsurpassed levels of patient care in a manner that is cost effective, and we believe this agreement with Sabal Therapeutics can achieve both of these core Company goals."

Because Naprosyn is dispensed in a liquid form, healthcare professionals can more accurately prescribe and adjust the dosage based on individual patient needs, especially for patients whose weight, medical condition or pain severity appropriately warrant flexible dosing versus the fixed dosage of tablets. In addition, because Naprosyn is dispensed in a liquid form rather than in a tablet, the difficulty that a number of people, especially those over 50 years of age, may have with swallowing pills is reduced.